Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Friday, November 13th. Analysts expect Inhibrx Biosciences to post earnings of ($2.45) per share and revenue of $1.90 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). On average, analysts expect Inhibrx Biosciences to post ($9.91) EPS for the current fiscal year and ($9.34) EPS for the next fiscal year.
Inhibrx Biosciences Stock Performance
INBX stock opened at $80.28 on Friday. The firm has a 50 day moving average of $99.62 and a 200-day moving average of $91.74. Inhibrx Biosciences has a 12 month low of $57.30 and a 12 month high of $155.29.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Inhibrx Biosciences
Insiders Place Their Bets
In other Inhibrx Biosciences news, Director Douglas Forsyth purchased 2,500 shares of the stock in a transaction on Tuesday, September 8th. The shares were purchased at an average price of $114.65 per share, with a total value of $286,625.00. Following the acquisition, the director directly owned 227,064 shares in the company, valued at approximately $26,032,887.60. The trade was a 1.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark Lappe purchased 25,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average price of $105.82 per share, with a total value of $2,645,500.00. Following the transaction, the chief executive officer owned 730,548 shares in the company, valued at approximately $77,306,589.36. The trade was a 3.54% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 62,540 shares of company stock valued at $6,347,507 and have sold 1,500 shares valued at $168,590. 18.26% of the stock is owned by corporate insiders.
Inhibrx Biosciences Company Profile
Inhibrx Biosciences, Inc is a biotechnology company focused on developing biologic medicines for serious and rare diseases. The company uses its proprietary protein-engineering and antibody-development platforms to create therapies designed to address conditions with limited treatment options.
Its lead investigational program was INBRX-101, an engineered recombinant protein developed for alpha-1 antitrypsin deficiency-associated lung disease. The company also advanced other potential treatments, including INBRX-109, an investigational therapy studied in certain solid tumors, and additional biologic candidates targeting oncology and other serious diseases.
Read More
- Five stocks we like better than Inhibrx Biosciences
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
